Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 16/20 | 0.60 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3813480 | 0.81 | KCNH2 (0.44) | PIN1 | |
| SCHEMBL1183253 | 0.79 | CYP2C9 (0.58) | PIN1MAPTMERTK | |
| SCHEMBL2260535 | 0.79 | ALDH1A1 (0.43) | PIN1MAPT | |
| SCHEMBL2259469 | 0.79 | KCNH2 (0.45) | PIN1 | |
| SCHEMBL3813659 | 0.76 | AR (0.39) | PIN1 | |
| SCHEMBL38657451 | 0.74 | KCNH2 (0.46) | MAPT | |
| SCHEMBL2264786 | 0.73 | CYP2C9 (0.40) | PIN1 | |
| SCHEMBL1028954 | 0.72 | PIN1 (0.69) | PIN1MAPTMERTK | |
| SCHEMBL12367100 | 0.71 | KCNH2 (0.39) | PIN1MAPT | |
| SCHEMBL12367097 | 0.71 | ABCC3 (0.38) | PIN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530655-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-10 | — | — | US | disclosed |
| US-20110263625-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | CORTE BART DE | 2011-10-27 | — | — | US | disclosed |
| US-8003789-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-08-23 | — | — | US | disclosed |
| US-7887845-B2 | Particle of a solid dispersion composed of a water soluble polymer and etravirine or salt thereof; etravirine FDA Orange book listed patent | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-15 | — | — | US | disclosed |
| US-7763631-B2 | Prodrugs of HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-27 | — | — | US | disclosed |
| US-20100172970-A1 | ANTIVIRAL COMPOSITIONS | VERRECK GEERT | 2010-07-08 | — | — | US | disclosed |
| US-20080176880-A1 | Activity against strains having acquired resistance nonnucleoside reverse transcriptase inhibitors; human alpha1 acid glycoprotein nonbinding; such as 4-[[(5-bromo-4,6-dichloro)-2-pyrimidinyl]amino]-benzonitrile | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-07-24 | — | — | US | disclosed |
| US-20070196478-A1 | ANTIVIRAL COMPOSITIONS | VERRECK GEERT | 2007-08-23 | — | — | US | disclosed |
| US-7241458-B1 | Antiviral compositions | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196478-A1 | ANTIVIRAL COMPOSITIONS | EIF2AK2, ZC3HAV1, RPL35 | PIN1 878/4885VCAM1 3200/4885MAPT 879/4885 |
| US-20080176880-A1 | Activity against strains having acquired resistance nonnucleoside reverse transcriptase inhibitors; human alpha1 acid glycoprotein nonbinding; such as 4-[[(5-bromo-4,6-dichloro)-2-pyrimidinyl]amino]-benzonitrile | ABCC1, MGAT1, RRM2 | PIN1 3646/4885VCAM1 781/4885MAPT 4585/4885 |
| US-20110263625-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | NSUN2, CCNO, POLR2H | PIN1 2174/4885VCAM1 3755/4885MAPT 4408/4885 |
| US-20100172970-A1 | ANTIVIRAL COMPOSITIONS | EIF2AK2, ZC3HAV1, RPL35 | PIN1 878/4885VCAM1 3200/4885MAPT 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.